Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on March 26, 2026, and filed on March 27, 2026. The filing details a share repurchase executed through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing focuses exclusively on capital structure and share repurchase activity. It does not contain operational financial data such as revenue, profit, cash flow, or margins.
- Shares Purchased (March 26, 2026): 345,000 ordinary shares.
- Price Range: Lowest 2,037.00p; Highest 2,072.00p.
- Volume-Weighted Average Price (VWAP): 2,053.34p.
- Estimated Transaction Value: Approximately £708,402 (calculated as 345,000 shares * 2,053.34p).
- Treasury Shares Held: 255,092,615 (post-transaction).
- Shares in Issue: 4,061,083,663 (excluding Treasury shares).
- Treasury Voting Rights: 6.28% of total voting rights.
Material Changes
Since the commencement of the current buyback agreement on February 17, 2026, GSK has purchased a total of 15,201,521 ordinary shares. The March 26 transaction represents a continuation of this programme, increasing the total treasury holding to 255,092,615 shares. The filing does not provide comparative financial performance data against prior periods.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance, outlook, or management commentary regarding future earnings or operational strategy. It includes a standard cautionary statement noting that forward-looking statements are subject to risks and uncertainties, referencing the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025. No unusual items or contingencies are disclosed in this specific report.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on February 17, 2026.
- Confirm the impact of the 6.28% treasury share holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" in the 2025 Form 20-F for context on the forward-looking statement disclaimer.
- Check subsequent filings for updates on the total volume of shares repurchased under the current programme.